Continuing chemotherapy and immunotherapy treatment in cancer patients with Covid-19 is not a risk to their survival, a study suggests.

It also recommends further research into the drug hydroxychloroquine, which appeared to benefit some patients.

The findings, from 890 infected cancer patients in the UK, Spain, Italy and Germany, could help identify who is most at risk from coronavirus.

Breast cancer patients had half the death rate of other patients.

The Imperial College London researchers who led the study - involving 19 different hospitals across Europe, including Hammersmith Hospital in London - say they now want to find out why.

They are also keen to investigate why UK cancer patients with Covid-19 in the study were more likely to die than in the three other countries.

For reading full text click the link.